MD Anderson Cancer Center entered into a collaboration with CytomX Therapeutics to research Probody-enabled chimeric antigen receptor natural killer cell therapies, to be known as ProCAR-NK cell therapies. MD Anderson will develop allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new targets for this […]
FDA granted Breakthrough Therapy Designation to pexidartinib (formerly PLX3397) for the treatment of tenosynovial giant cell tumor where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity. Currently, there is no FDA-approved systemic therapy for the treatment of TGCT. The designation was granted based on results from an […]
Researchers from The Cancer Genome Atlas Network recently published two studies—one identifying seven distinct molecular subtypes of prostate cancer, and one exploring the genetic drivers of papillary renal cell carcinoma.
FDA approved Imlygic (talimogene laherparepvec) as the first oncolytic viral therapy in the U.S.
FDA granted Priority Review for defibrotide for the treatment of patients with hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, with evidence of multi-organ dysfunction following hematopoietic stem-cell transplantation. FDA review of the new drug application is expected to be completed by March 31, 2016. The application, submitted by Jazz Pharmaceuticals plc, includes safety... […]
FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. The agency previously granted Priority Review and orphan drug designations for Onivyde. The effectiveness of Onivyde was demonstrated in a phase III, three-arm, randomized, open label study of... […]
FDA granted Priority Review to MCNA, developed by Telesta, for the treatment of high-risk, non-muscle invasive bladder cancer patients who are refractory or relapsing from BCG front-line treatment.
Imbruvica was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent.
FDA approved Imlygic (talimogene laherparepvec) as the first oncolytic viral therapy in the U.S.
FDA granted de novo clearance to SonaCare Medical LLC to market the Sonablate 450 in the U.S. for the ablation of prostate tissue.
